Helsinn and Mundipharma have signed an exclusive agreement for the distribution and licensing of NEPA, an investigational oral fixed combination of netupitant and palonosetron developed for the prevention of chemotherapy-induced nausea and vomiting (CINV), in Brazil. Read the full story

Evaluation agreements allow a party to the deal to obtain rights to a technology or compound, subject to... Read the full story

The term option within an deal refers to an integral part of an agreement already entered by the parties... Read the full story

Covidien has entered into a biotech deal with a definitive agreement with Integra LifeSciences Corporation to sell its Confluent Surgical product line.

Read the full story